美托洛尔联合曲美他嗪治疗对冠心病心绞痛患者血浆CRP、BNP、TNF-α水平及疼痛的影响

Effects of Metoprolol Combined with Trimetazidine on Plasma CRP,BNP,TNF-Alpha Levels and Pain in Patients with Coronary Heart Disease and Angina Pectoris

目的:探讨美托洛尔联合曲美他嗪治疗对冠心病心绞痛患者血浆CRP、BNP、TNF-α水平及疼痛的影响。方法:回顾性分析2015年6月~2016年5月我院心血管内科治疗冠心病心绞痛90例临床案例,按给药方式分为联合组及单一组,各45例。单一组实施常规治疗及曲美他嗪治疗,联合组在此基础上加上美托洛尔,疗程均为30d。对比分析两组患者治疗效果、血浆CRP、BNP、TNF-α水平及心绞痛情况变化。结果:两组患者治疗前后心绞痛发作情况均得到明显改善,而治疗后联合组患者发作次数、持续时间及心绞痛积分均明显低于单一组,差异有统计学意义(P<0.05)。结论:美托洛尔联合曲美他嗪治疗对冠心病心绞痛患者可明显改善患者心绞痛发作情况及提高治疗效果,降低冠心病心绞痛患者血浆CRP、BNP、TNF-α水平,促进患者恢复。

Object ive： To investigate the effect of metoprolol combined with trimetazidine on the levels of plasma CRP, BNP, TNF- alpha and pain in patients with coronary heart disease （ CHD）. Metl iods： 90 coronary heart disease angina pectoris patients were retrospective-ly analyzed from June 2015 to May 2016 from in hospital,according to the dosing methods,all patients were divided into experimental group and control group. The control group was given sibutramine. Experimental group was given sibutramine of treatment of 30 days. Compared two groups of patients＇ treatment,plasma CRP,BNP,TNF alpha level changes and anginapectoris. Results： TNF alpha,BNP and CRP levels of the experimental group were lower than combined trimetazidine treatment can obviously improve patients with angina pectoris attacks in patients with pectoris and improve the treatment effect , reduce plasma CRP in patients with coronary heart disease angina pectoris , BNP , TNF alpha level, promote patients recover.